Three Cannabis Stocks Offer Bargain Entry Points Amid Market Selloff

The cannabis market had opened 2021 with genuine momentum. Legalization was spreading, company fundamentals were tightening, and investors were buying. Then, in late February, the sector hit a wall. Speculative trading fears triggered a sharp pullback that wiped out weeks of gains. But for investors with a longer view, the sudden discount created something worth examining: three established cannabis companies, all trading at steep discounts, all showing signs of operational improvement beneath the noise.

Aurora Cannabis had just reported second-quarter results that missed analyst expectations on the surface. But the details told a different story. The company's adjusted EBITDA losses had shrunk dramatically—from $53.1 million a year earlier to $12.1 million in the recent quarter. Sales were climbing. Operating expenses were falling. The company was burning less cash while growing revenue, which is the trajectory investors actually care about. As of mid-February, Aurora held $565 million in cash, a healthy cushion for a company in growth mode. The stock had fallen roughly 50 percent from its recent peak, and its price-to-book multiple sat at 0.8, suggesting the market was pricing in far worse outcomes than the numbers supported. Aurora had also built meaningful market share in medical cannabis across Canada and internationally, with operations expanding in Germany, Israel, France, and Australia. The company was betting on premium consumer products and had launched Reliva, a CBD brand that was gaining traction in the U.S. market.

Aphria presented a different kind of case. It was one of the rare cannabis companies actually reporting positive adjusted EBITDA—not once, but for seven consecutive quarters. That consistency mattered. The company had captured significant share in Canada's consumer segment, particularly in vape and dried flower products. In January, it had introduced higher-potency topicals, a new product category that could drive sales forward. But the real growth engine lay in the United States. Aphria had recently acquired SweetWater Beverage Company, gaining access to manufacturing, marketing, and distribution infrastructure in a market where cannabis companies were still scrambling to build scale. More significantly, Aphria had announced a proposed merger with Tilray, a deal that would create a combined entity with global market consolidation potential. The two companies projected $100 million in synergies over the first two years post-merger. Despite these growth catalysts, Aphria was trading 44.5 percent below its 52-week high, offering what long-term investors might see as a rare entry point.

Canopy Growth, the sector's largest player, had also been hammered. The stock was down more than 40 percent from its 52-week peak. Yet in its most recent quarterly report, the company had beaten analyst expectations and offered a three-year outlook that suggested management believed in the business. Canopy projected top-line growth of 40 to 50 percent annually over the next three years, a rate that would require both market expansion and share gains. The company was not yet profitable, but management expected to report positive adjusted EBITDA by the second half of fiscal 2022, with margins reaching 20 percent by 2024. The path to profitability hinged on closing underperforming production facilities, reducing headcount, and continuing to cut selling, general, and administrative expenses. Canopy had $1.59 billion in cash as of year-end, enough to fund growth initiatives without needing to raise capital at depressed valuations.

What tied these three together was not just the discount—though that mattered—but the underlying shift in the sector's maturity. These were no longer pure-play speculations. They were companies with real revenue, improving unit economics, and paths to profitability that management could articulate with specificity. The recent selloff had been driven by fear and rotation, not by deteriorating fundamentals. For investors willing to look past the noise, the bargain prices offered a rare alignment: a sector with genuine long-term growth prospects, companies showing operational discipline, and valuations that no longer priced in perfection.